Coya Therapeutics Secures $34.1M Financing, Extends Runway, Advances ALS & FTD Trials
summarizeSummary
Coya Therapeutics reported its fiscal year 2025 financial results and provided a comprehensive corporate update, highlighted by significant financing and clinical progress. The company successfully secured $23.0 million through an upsized public offering and an additional $11.1 million via a private placement, totaling $34.1 million. These capital raises are highly material for a company of Coya's size, extending its cash runway into the second half of 2027 and significantly de-risking its operations. Operationally, Coya launched the ALSTARS Phase 2 trial for ALS, which is actively enrolling patients, and received FDA IND acceptance for COYA 302 for the treatment of frontotemporal dementia (FTD). The company also reported increased collaboration revenues from milestone payments, reflecting positive pipeline advancements. Investors will now closely monitor the continued enrollment of the ALSTARS trial and the planned initiation of the Phase 2a FTD study in the second half of 2026.
At the time of this announcement, COYA was trading at $4.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.8M. The 52-week trading range was $3.94 to $7.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.